OCA
CNTX icon

Octagon Capital Advisors’s Context Therapeutics CNTX Stock Holding History

Octagon Capital Advisors’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.8M Buy
+5,250,000
New +$12.3M 1.52% 20

Other funds holding CNTX

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Octagon Capital Advisors's CNTX Position: Q1 2026 in Review

Octagon Capital Advisors opened a new position in Context Therapeutics (CNTX) in Q1 2026: 5,250,000 shares worth $13.8M. The stake represents 1.52% of the portfolio and ranks #20 among its holdings.

59 funds tracked by Wall St. Rank hold CNTX as of Q1 2026.

  • Octagon Capital Advisors held 5,250,000 shares of Context Therapeutics worth $13.8M as of Q1 2026.
  • Context Therapeutics was a new Octagon Capital Advisors position in Q1 2026.
  • Context Therapeutics made up 1.52% of Octagon Capital Advisors's portfolio in Q1 2026, its #20 holding.
  • 59 funds tracked by Wall St. Rank held Context Therapeutics as of Q1 2026.

Based on Octagon Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.